僵直性脊椎炎市場:KOL的洞察

本報告提供全球僵直性脊椎炎市場相關調查，提供市場概要，以及已通過核准治療方法，開發平台趨勢，未來預測等資訊。

目錄

摘要整理

治療流程

調查目的

TNF抑制劑

• 市售療法
  • Remicade(Infliximab，Janssen Biotech/Merck &Co.)，Enbrel(Etanercept，Pfizer/Amgen)，Simponi(gorimumabu，Janssen Biotech/Merck &Co.)，Humira(Adalimumab，AbbVie)，Cimzia(serutorizumabupegoru，UCB)(12)

IL-17抑制劑

• 已通過核准治療方法
  • Cosentyx（蘇金單抗，諾華）
  • Taltz（ixekizumab，禮來公司）
  • Bimzerx（bimekizumab、UCB）
• 管道處理
  • Izoquivep（Aceriline/Affibody）

JAK抑制劑

• 核准的治療方法
  • Rinvoq（upadacitinib、艾伯維）
  • Xeljanz（託法替尼，輝瑞）
• 管道處理
  • Gyseleca（filgotinib，Galapagos NV）

其他作用機轉

• 管道處理
  • Namilumab（安進/武田/Izana）

未來的治療範例

附錄

What does the future AS therapy landscape look like? Will the domination of anti-TNFs continue? How do KOLs assess the potential of anti-IL17 strategies? Could a re-evaluation of safety concerns see wider use of JAK inhibitors such as AbbVie's Rinvoq and Pfizer's Xeljanz? What pipeline therapies could bring new treatment options? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to KOL Bulletins.

Table of Contents

Executive summary (8)

Treatment algorithm (1)

Research objectives (5)

TNF inhibitors (12)

• Marketed therapies (12)
  • Remicade (infliximab; Janssen Biotech/Merck & Co.); Enbrel (etanercept; Pfizer/Amgen); Simponi (golimumab; Janssen Biotech/Merck & Co.); Humira (adalimumab; AbbVie); Cimzia (certolizumab pegol; UCB) (12)

IL-17 inhibitors (34)

• Approved therapies (28)
  • Cosentyx (secukinumab; Novartis) (10)
  • Taltz (ixekizumab; Lilly) (9)
  • Bimzelx (bimekizumab; UCB) (9)
• Pipeline drugs (6)
  • Izokibep (Acelyrin/Affibody) (6)

JAK inhibitors (18)

• Approved therapies (14)
  • Rinvoq (upadacitinib; AbbVie) (8)
  • Xeljanz (tofacitinib; Pfizer) (6)
• Pipeline therapies (4)
  • Jyseleca (filgotinib; Galapagos NV) (4)

Other mechanisms of action (6)

• Pipeline therapies (6)
  • Namilumab (Amgen/Takeda/Izana) (6)

Future treatment paradigm (11)

• Key insights summary (11)

Appendix (4)

• KOL details (4)
  • KOLs from North America (1)
  • KOLs from Europe (2)